Prokinetics for Gastroparesis: Metoclopramide, Domperidone, Erythromycin, and Prucalopride Compared

Prokinetic medications — drugs that accelerate gastrointestinal motility — are the primary pharmacological treatment for gastroparesis. By speeding gastric emptying, they address the underlying physiological problem rather than just managing symptoms. However, the available prokinetics have significant differences in mechanism, effectiveness, side effect profile, and availability, and choosing the right agent requires careful consideration of each patient's individual circumstances.

This guide covers the four prokinetics most commonly used for gastroparesis: metoclopramide, domperidone, erythromycin, and prucalopride.

Metoclopramide (Reglan)

Mechanism

Metoclopramide is a dopamine D2 receptor antagonist and a 5-HT4 receptor agonist. By blocking D2 receptors in the stomach and small intestine, it removes the inhibitory effect of dopamine on gastric motility, accelerating gastric emptying. By activating 5-HT4 receptors, it enhances the release of acetylcholine from enteric neurons, further stimulating motility. It also has central antiemetic effects through D2 receptor blockade in the chemoreceptor trigger zone.

Effectiveness

Metoclopramide is the only FDA-approved medication for gastroparesis in the United States. Clinical trials demonstrate modest improvement in gastric emptying rates and symptom scores compared to placebo. However, the magnitude of benefit is variable — some patients respond well, others see minimal improvement.

Dosing

Typical dosing is 5–10 mg taken 30 minutes before meals and at bedtime (4 times daily). It is available as tablets, oral solution, and injectable forms.

Side Effects and Risks

Tardive dyskinesia (TD) is the most serious concern with metoclopramide. TD is a potentially irreversible movement disorder characterized by repetitive, involuntary movements of the face, tongue, and limbs. The FDA has issued a black box warning for TD with metoclopramide use beyond 12 weeks. The risk increases with dose and duration of use and is higher in older patients and women.

Extrapyramidal symptoms (EPS) — including acute dystonia (muscle spasms), akathisia (restlessness), and parkinsonism — can occur, particularly at higher doses.

Drowsiness and fatigue are common, particularly at the start of treatment.

Depression and anxiety are reported by some patients, possibly related to dopamine blockade in the central nervous system.

Hyperprolactinemia — elevated prolactin levels — can cause galactorrhea (breast milk production), menstrual irregularities, and sexual dysfunction.

Practical Considerations

Due to the TD risk, metoclopramide should be used at the lowest effective dose for the shortest necessary duration. Many gastroparesis specialists limit use to 12 weeks or use it intermittently rather than continuously. It is generally not recommended for long-term use.

Despite its limitations, metoclopramide remains widely used because it is inexpensive, widely available, and effective for many patients when used appropriately.

Domperidone

Mechanism

Domperidone is a dopamine D2 receptor antagonist, similar in mechanism to metoclopramide. However, unlike metoclopramide, domperidone does not cross the blood-brain barrier (or crosses it minimally), which means it has fewer central nervous system side effects — no tardive dyskinesia, no extrapyramidal symptoms, and less drowsiness.

Domperidone acts primarily on peripheral D2 receptors in the stomach and small intestine, accelerating gastric emptying. It also has central antiemetic effects through D2 blockade in the area postrema (which is outside the blood-brain barrier).

Effectiveness

Domperidone is generally considered at least as effective as metoclopramide for gastroparesis, with a significantly better side effect profile. Many gastroparesis specialists consider it the preferred prokinetic when available.

Availability

Domperidone is not FDA-approved in the United States and is not commercially available through standard US pharmacies. However, it can be obtained through:

• FDA Expanded Access (Compassionate Use) program: Physicians can apply for individual patient access through the FDA for patients who have failed other treatments.
• Compounding pharmacies: Compounded domperidone is available with a prescription from US compounding pharmacies.
• International pharmacies: Domperidone is available over-the-counter or by prescription in Canada, the UK, Europe, Australia, and many other countries.

Dosing

Typical dosing is 10 mg taken 30 minutes before meals and at bedtime (4 times daily). Some patients require 20 mg per dose.

Side Effects and Risks

QT prolongation is the primary concern with domperidone. It can prolong the QT interval on the ECG, which in rare cases can lead to serious cardiac arrhythmias (torsades de pointes). The risk is higher at doses above 30 mg/day, in patients with pre-existing cardiac conditions, in elderly patients, and when combined with other QT-prolonging medications.

Baseline and periodic ECG monitoring is recommended for patients on domperidone.

Hyperprolactinemia occurs with domperidone, similar to metoclopramide.

Headache is reported by some patients.

Notably absent compared to metoclopramide: tardive dyskinesia, extrapyramidal symptoms, and significant CNS effects.

Erythromycin

Mechanism

Erythromycin is a macrolide antibiotic that, at low doses, acts as a motilin receptor agonist. Motilin is a gastrointestinal hormone that stimulates the migrating motor complex (MMC) — the between-meal contractions that sweep the stomach and small intestine. By mimicking motilin, erythromycin produces powerful gastric contractions that accelerate emptying.

Effectiveness

Erythromycin is one of the most potent prokinetics available and can produce dramatic short-term improvement in gastric emptying. However, its effectiveness diminishes significantly with continued use due to tachyphylaxis — downregulation of motilin receptors with repeated stimulation. Most patients experience significant loss of effectiveness within 4 weeks of continuous use.

Dosing

For gastroparesis, erythromycin is used at much lower doses than for its antibiotic effects: typically 50–125 mg (oral) or 3 mg/kg (intravenous) taken 30 minutes before meals. Intravenous erythromycin is highly effective for acute gastroparesis exacerbations requiring hospitalization.

Side Effects and Risks

Tachyphylaxis is the primary limitation, as described above.

Gastrointestinal side effects — nausea, vomiting, abdominal cramping, and diarrhea — are common, particularly at higher doses. These can be paradoxically worse than the gastroparesis symptoms being treated.

QT prolongation — erythromycin prolongs the QT interval and carries a risk of cardiac arrhythmias, particularly when combined with other QT-prolonging medications or in patients with cardiac conditions.

Drug interactions — erythromycin inhibits CYP3A4, a major drug-metabolizing enzyme, and can significantly increase blood levels of many medications including statins, calcium channel blockers, and immunosuppressants.

Antibiotic resistance — long-term use of erythromycin as a prokinetic can contribute to antibiotic resistance, though the low doses used for motility are less concerning than therapeutic antibiotic doses.

Practical Considerations

Due to tachyphylaxis, erythromycin is most useful for:

• Acute gastroparesis exacerbations (intravenous use in hospital)
• Short-term "rescue" therapy during flares
• Intermittent use (e.g., 2 weeks on, 2 weeks off) to reduce tachyphylaxis

It is generally not recommended for continuous long-term use.

Prucalopride (Motegrity)

Mechanism

Prucalopride is a highly selective 5-HT4 receptor agonist. By activating 5-HT4 receptors throughout the gastrointestinal tract, it stimulates the release of acetylcholine from enteric neurons, enhancing coordinated peristaltic contractions from the esophagus to the colon.

Unlike metoclopramide (which also has 5-HT4 agonist activity), prucalopride is highly selective for 5-HT4 receptors and does not have significant dopamine receptor activity, avoiding the neurological side effects of metoclopramide.

Availability and Approval

Prucalopride is FDA-approved for chronic idiopathic constipation in adults. It is not FDA-approved specifically for gastroparesis, but it is increasingly used off-label for gastroparesis, particularly in patients with comorbid constipation or slow-transit constipation.

Effectiveness for Gastroparesis

Clinical evidence for prucalopride in gastroparesis is emerging but still limited compared to metoclopramide and domperidone. Several small studies and case series have shown improvement in gastric emptying rates and symptom scores. A larger randomized controlled trial is ongoing.

Many gastroparesis specialists use prucalopride as a second-line or adjunct agent, particularly for patients who have failed or cannot tolerate metoclopramide and domperidone.

Dosing

Standard dosing is 2 mg once daily (1 mg once daily in elderly patients or those with severe renal impairment).

Side Effects

Headache is the most common side effect, occurring in approximately 30% of patients in clinical trials. It is usually mild and often resolves after the first few days of treatment.

Nausea, diarrhea, and abdominal pain occur in some patients, particularly in the first week of treatment.

No QT prolongation — unlike domperidone and erythromycin, prucalopride does not prolong the QT interval, making it safer for patients with cardiac conditions or those on multiple QT-prolonging medications.

No neurological side effects — no tardive dyskinesia, no extrapyramidal symptoms.

Comparison Summary

Choosing a Prokinetic

For most gastroparesis patients, the choice of prokinetic is guided by:

1. Availability: In the US, metoclopramide is the most accessible. Domperidone requires more effort to obtain but is preferred by many specialists.
2. Side effect tolerance: Patients who cannot tolerate metoclopramide's CNS effects should try domperidone (if accessible) or prucalopride.
3. Cardiac history: Patients with QT prolongation or significant cardiac disease should avoid domperidone and erythromycin; prucalopride is the safest option.
4. Comorbid constipation: Prucalopride addresses both gastroparesis and constipation simultaneously.
5. Acute vs. chronic use: Erythromycin is most useful for acute exacerbations; domperidone or prucalopride for long-term management.

Many patients require trials of multiple prokinetics before finding the one that provides the best balance of effectiveness and tolerability. Working with a gastroenterologist experienced in gastroparesis management is essential for navigating these choices.